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Abstract
Massive research efforts are now underway to develop a
cure for HIV infection, allowing patients to discontinue lifelong
combination antiretroviral therapy (ART). New latency-reversing
agents (LRAs) may be able to purge the persistent reservoir of
latent virus in resting memory CD4+ T cells, but the degree of
reservoir reduction needed for cure remains unknown. Here we
use a stochastic model of infection dynamics to estimate the effi-
cacy of LRA needed to prevent viral rebound after ART interrup-
tion. We incorporate clinical data to estimate population-level pa-
rameter distributions and outcomes. Our findings suggest that ap-
proximately 2,000-fold reductions are required to permit a major-
ity of patients to interrupt ART for one year without rebound and
that rebound may occur suddenly after multiple years. Greater
than 10,000-fold reductions may be required to prevent rebound
altogether. Our results predict large variation in rebound times
following LRA therapy, which will complicate clinical manage-
ment. This model provides benchmarks for moving LRAs from
the lab to the clinic and can aid in the design and interpretation
of clinical trials. These results also apply to other interventions
to reduce the latent reservoir and can explain the observed return
of viremia after months of apparent cure in recent bone marrow
transplant recipients and an immediately-treated neonate.
Significance Statement
HIV infection cannot be cured by current antiretroviral drugs,
due to the presence of long-lived latently-infected cells. New
anti-latency drugs are being tested in clinical trials, but major
unknowns remain. It is unclear how much latent virus must be
eliminated for a cure, which remains difficult to answer empiri-
cally due to few case studies and limited sensitivity of viral reser-
voir assays. In this paper, we introduce a mathematical model
of HIV dynamics to calculate the likelihood and timing of viral
rebound following anti-latency treatment. We derive predictions
for the required efficacy of anti-latency drugs, and demonstrate
that rebound times may be highly variable and occur after years
of remission. These results will aid in designing and interpreting
HIV cure studies.
Introduction
The latent reservoir (LR) for HIV-1 is a population of long-
lived resting memory CD4+ T cells with integrated HIV-1
DNA [1]. After establishment during acute infection [2], it in-
creases to 105− 107 cells and then remains stable. As only repli-
cating virus is targeted by antiretroviral therapy (ART), latently
infected cells persist even after years of effective treatment [3; 4].
Cellular activation leads to virus production and, if treatment is
interrupted, viremia rebounds within weeks [5]. Several molec-
ular mechanisms maintain latency, including epigenetic modifi-
cations, transcriptional interference from host genes, and the ab-
sence of activated transcription factors [6; 7; 8; 9].
Major efforts are underway to identify pharmacologic agents
that reverse latency by triggering the expression of HIV-1 genes
in latently infected cells, with the hope that cell death from vi-
ral cytopathic effects or cytolytic immune responses follows, re-
ducing the size of the LR [10; 11]. Collectively called latency-
reversing agents (LRAs), these drugs include histone deacetylase
inhibitors [12; 13; 14], protein kinase C activators [15; 16; 17;
18], and the bromodomain inhibitor JQ1 [19; 20; 21]. While
LRAs are the subject of intense research, it is unclear how much
the LR must be reduced to enable patients to safely discontinue
ART.
The feasibility of reservoir reduction as a method of HIV-1 cure
is supported by case studies of stem-cell transplantation [22; 23]
and, more recently, early treatment initiation [24; 25], which have
allowed patients to interrupt treatment for months or years with-
out viral rebound. The dramatic reductions in reservoir size ac-
companying these strategies stands in stark contrast to the actions
of current LRAs, which induce only a fraction of latent virus in
vitro [26; 27] and have not produced a measurable decrease in LR
size in vivo [12; 13; 28]. It unclear how patient outcomes depend
on reservoir reduction between these extremes, nor even whether
a reduction that falls short of those achieved with stem-cell trans-
plantation will bring any clinical benefit. LRA research needs to
address the question: how low must we go?
In the absence of clinical data, mechanistic mathematical mod-
els can serve as a framework to predict results of novel interven-
tions and plan clinical trials. When results do become available,
the models can be tested and refined. Mathematical models have
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Figure 1: Schematic of LRA treatment and stochastic model of rebound
following interruption of ART. a) Proposed treatment protocol, illustrating
possible viral load and size of LR before and after LRA therapy. When
ART is started, viral load decreases rapidly and may fall below the limit of
detection. The LR is established early in infection (not shown) and decays
very slowly over time. When LRA is administered, the LR declines. After
discontinuation of ART, the infection may be cleared, or viremia may even-
tually rebound. b) LRA efficacy is defined by the parameter q, the fraction
of the LR remaining after therapy, which determines the initial conditions
of the model. The stochastic model of viral dynamics following interrup-
tion of ART and LRA tracks both latently infected resting CD4+ T cells
(rectangles) and productively infected CD4+ T cells (ovals). Each arrow
represents an event that occurs in the model. Alternate models consider-
ing homeostatic proliferation and turnover of the LR are discussed in the
Methods and Supplementary Methods. Viral rebound occurs if at least
one remaining cell survives long enough to activate and produce a chain
of infection events leading to detectable infection (plasma HIV-1 RNA >
200 c ml−1).
a long tradition of informing HIV-1 research and have been par-
ticularly useful in understanding HIV-1 treatment. Previous mod-
els have explained the multi-phasic decay of viremia during an-
tiretroviral therapy [29], the initial seeding of the LR during acute
infection [30], the limited inflow to the LR during treatment [31],
the dynamics of viral blips [32], and the contributions of the LR
to drug resistance [33]. No model has yet been offered to describe
the effect of LRAs. Here we present a novel modeling framework
to predict the degree of reservoir reduction needed to prevent vi-
ral rebound following ART interruption. The model can be used
to estimate the probability that cure is achieved, or, barring that
outcome, to estimate the length of time following treatment inter-
ruption before viral rebound occurs (Fig. 1a).
Results
Determination of key viral dynamic parameters governing
patient outcomes
We employ a stochastic model of HIV-1 reservoir dynamics
and rebound that, in its simplest form, tracks two cell types: pro-
ductively infected activated CD4+ T cells and latently infected
resting CD4+ T cells (Fig. 1b). A latently infected cell can either
activate or die, each with a particular rate constant. An actively
infected cell can produce virions, resulting in the active infection
of some number of other cells, or it can die from other causes
without producing virions that infect other cells; in the latter case,
cytotyoxic T lymphocyte (CTL) killing, errors in viral reverse
transcription, or other problems upstream of virion production
may prevent further infection. The model only tracks the initial
stages of viral rebound, when target cells are not yet limited. A
full description is provided in the Methods and Supplementary
Methods.
The initial conditions for the dynamic model depend on the
number of latently infected cells left after LRA therapy. LRA
efficacy is defined by the fraction q of the LR that remains fol-
lowing treatment. The model tracks each latent and active cell
to determine whether viral rebound occurs, and if so, how long
it takes. Importantly, no single activated cell is guaranteed to
re-establish the infection, as it may die prior to infecting other
cells. Even if it does infect others, those cells likewise may die
prior to completing further infection. This possibility is a gen-
eral property of stochastic models, and the specific value for the
establishment probability depends on the rates at which infection
and death events occur. Our goal is to calculate the probability
that at least one of the infected cells remaining after therapy es-
capes extinction and causes viral rebound, and if so, how long it
takes. If all cells die, then rebound never occurs and a cure is
achieved. As the model only describes events after completion
of LRA therapy, our results are independent of the therapy pro-
tocol or mechanism of action. Using both stochastic simulations
and theoretical analysis of this model, we find that the probability
and timing of rebound relies on four key parameters: the decay
rate of the LR in the absence of viral replication (δ), the rate at
which the LR produces actively infected cells (A), the probabil-
ity that any one activated cell will produce a rebounding infection
before its lineage dies (PEst), and the net growth rate of the in-
fection once restarted (r). Estimates of these four parameters are
provided in Table 1 and Supplementary Fig.1. After therapy, the
rate at which the LR produces actively infected cells is reduced
to qA. The probability that an individual successfully clears the
infection is:
PClr(q) ≈ e−qAPEst/δ. (1)
The expression qAPEst/δ approximates the expected number of
fated-to-establish cells that will ever exit from the LR, explaining
the Poisson form of this expression. In the Supplementary Meth-
ods, we provide the full derivation, as well as a formula (Eq. S8)
for the probability that rebound occurs a given number of days
following treatment interruption (a function of δ, A, PEst, r, and
efficacy q). Of note, the initial size of the reservoir itself is not in-
cluded among these parameters: while it factors into both A (the
product of the pre-LRA reservoir size and the per-cell activation
rate), and q (the ratio of post-LRA to pre-LRA reservoir size), it
does not independently influence outcomes. Both of these formu-
las provide an excellent match to explicit simulation of the model
(Fig. 2). The key assumption required for the analysis is that r
greatly exceeds δ; since viral doubling times during rebound are
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measured on the order of a few days, while LR decay is measured
on the order of many months or years, this assumption is expected
to hold. Likelihood-based inference can therefore proceed by ef-
ficient computation of rebound probabilities (using equation S8),
rather than by time-consuming stochastic simulation.
Outcomes depend only on the four parameters above even in
more complex models of viral dynamics including other features
of T cell biology and the HIV lifecycle (Supplementary Meth-
ods). Alternate models studied include explicit tracking of free
virus with varying burst sizes, an “eclipse phase” during which an
infected cell produces no virus, proliferation of cells upon reacti-
vation, maintenance of the LR by homeostatic proliferation, and
either a constant or Poisson-distributed number of infected cells
produced by each cell (Supplementary Figs. 2-7). If prolifera-
tion of latently infected cells is subject to high variability, e.g., by
“bursts” of proliferation, then rebound time and cure probability
increase slightly beyond the predictions of the basic model (Sup-
plementary Figs. 6 and 7). No other modification to the model
altered outcomes. Outcomes of LRA therapy therefore are likely
to be insensitive to details of the viral lifecycle; accordingly, few
parameters must be estimated to predict outcomes.
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Figure 2: Clearance probabilities and rebound times following LRA ther-
apy predicted from model using point estimates for the parameters (Ta-
ble 1). “LRA log-efficacy” is the number of orders of magnitude by which
the latent reservoir size is reduced following LRA therapy (− log10(q)). a)
Probability that the LR is cleared by LRA. Clearance occurs if all cells in
the LR die before a reactivating lineage leads to viral rebound. b) Median
viral rebound times (logarithmic scale), among patients who do not clear
the infection. c) Survival curves (Kaplan-Meier plots) show the percent-
age of patients who have not yet experienced viral rebound, plotted as a
function of the time (logarithmic scale) after treatment interruption. Solid
lines represent simulations, and circles represent approximations from the
branching process calculation. All simulations included 104 to 105 patients
with identical viral dynamic parameter values.
Predicted prospects for eradicating infection or delaying time
to rebound
Using best estimates of parameters derived from previously re-
ported data (Table 1), we can explore the likely outcomes of in-
terventions that reduce the latent reservoir. The best outcome of
LRA therapy, short of complete and immediate eradication, is that
so few latently infected cells survive that none reactivate and start
a resurgent infection during the patient’s lifespan. In this case,
LRA has essentially cleared the infection and a cure is achieved.
We simulated the model to predict the relationship between LRA
efficacy and clearance (Fig. 2a). We find that the reservoir must
be reduced 10,000-fold before half of patients are predicted to
clear the infection.
If LRA therapy fails to clear the infection, the next-best out-
come is extension of the time until rebound, defined as plasma
HIV-1 RNA ≥ 200 c ml−1. We computed the relationship be-
tween LRA efficacy and median time until rebound among pa-
tients who do not clear the infection (Fig. 2b). Roughly a 2,000-
fold reduction in the reservoir size is needed for median rebound
times of 1 year. Only modest (∼ 2-fold) increases in median re-
bound time are predicted for up to 100-fold reductions in LR size.
In this range, the rebound time is independent of latent cell lifes-
pan (decay rate δ) and is driven mainly by the reactivation rate (A)
and the infection growth rate (r). The curve inflects upward (on
a log scale) at ≈100-fold reduction and eventually reaches a ceil-
ing as clearance of the infection becomes the dominant outcome.
The upward inflection results from a change in the forces govern-
ing viral dynamics. If the reservoir is large (little reduction), then
cells activate frequently, and the dominant component of rebound
time is the time that it takes for virus from the many available ac-
tivated cells to grow exponentially to rebound levels; the system
is in a growth-limited regime. If the reservoir is small (large re-
duction), the dominant component is instead the expected waiting
time until activation of the first cell fated to establish a rebounding
lineage; the system is in an activation-limited regime. Since wait-
ing time is roughly exponentially distributed, times to rebound in
this regime can vary widely among patients on the same therapy,
even with identical values of the underlying parameters.
Survival curves, plotting the fraction of simulated patients
maintaining virologic suppression over time, demonstrate the ex-
treme interpatient variability and long follow-up times required
for LRA therapy (Fig. 2c). For less than 100-fold reductions
in LR size, simulated patients uniformly rebound within a few
months, since rebound dynamics are not in the activation-limited
regime. If therapy decreases LR size 1,000-fold, then ∼55% of
patients are predicted to delay rebound for at least six months.
However, of these patients, 47% suffer rebound in the following
six months. Higher reservoir reductions lead to clearance in many
patients. In others, rebound may still occur after years of apparent
cure, posing a challenge for patient management.
Earlier work suggested a shorter reservoir half-life of 6 months
[37], indicating that dramatic decreases in LR size would occur
after 5 or more years of suppressive ART even in the absence
of LRA therapy. We consider the prospects for HIV eradication
or long treatment interruptions with this faster reservoir decay
rate (Fig. 3b). In this optimistic scenario, only 1,500-fold reduc-
tions are needed for half of patients to clear the LR, and rebound
becomes highly unlikely after a few years. Alternatively, in a
worst-case scenario where latent cell death is perfectly balanced
by homeostatic proliferation such that the reservoir does not de-
cay at all (δ = 0), much higher efficacies are needed to achieve
beneficial patient outcomes (Fig. 3c).
Setting treatment goals with uncertainty considerations
We conducted a full uncertainty analysis of the model, by si-
multaneously varying all parameters over their entire ranges (Ta-
ble 1, Supplementary Fig. 1). For each simulated patient, val-
ues for the three parameters δ, A, and r were sampled indepen-
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Parameter Symbol Estimation Method Source Best Estimate Distribution
LR decay rate δ
Long-term ART(
δ = ln(2)/τ1/2
) [3; 4] 5.2× 10−4 d−1 δ ∼ N (5.2, 1.6)× 10−4 d−1
LR exit rate A Viral rebound after
ART interruption [5; 34]
57 cells d−1 log10(A) ∼ N (1.76, 1.0)
Growth rate r 0.4 d−1 log10(r) ∼ N (−0.40, 0.19)
Establishment probability PEst
Population genetic
modeling [35; 36] 0.069
(composite distribution;
see Methods)
Table 1: Estimated values for the key parameters of the stochastic viral dynamics model
Notation X ∼ N (µ, σ) means that X is a random variable drawn from a normal distribution with mean µ and standard deviation σ.
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Figure 3: Predicted LRA therapy outcomes, accounting for un-
certainty in patient parameter values. a) Full uncertainty analysis
where all viral dynamics parameters are sampled for each patient
from the distributions provided in Table 1. b) A best-case scenario
where the reservoir half-life is only 6 months (δ = 3.8×10−3 d−1).
All patients have the same underlying viral dynamic parameters,
otherwise given by the point estimates in Table 1. c) A worst-case
scenario where the reservoir does not decay because cell death
is balanced by homeostatic proliferation (δ = 0). I) Probability
that the LR is cleared by LRA. Clearance occurs if all cells in the
LR die before a reactivating lineage leads to viral rebound. “LRA
log-efficacy” is the number of orders of magnitude by which the la-
tent reservoir size is reduced following LRA therapy (− log10(q)).
II) Median viral rebound times (logarithmic scale), among patients
who do not clear the infection. III) Survival curves (Kaplan-Meier
plots) show the percentage of patients who have not yet experi-
enced viral rebound, plotted as a function of the time (logarithmic
scale) after treatment interruption. All simulations included 104 to
105 patients.
dently from their respective distributions, while PEst was sam-
pled from a conditional distribution that depends on r (see Meth-
ods). Results for this simulated cohort are similar to those for the
point estimates, with greater interpatient variation in outcomes
(Fig. 3a). This variation makes the survival curves less steep:
cure is slightly more likely at low efficacy, but slightly less likely
at high efficacy. As expected from Equation (1), cure is more
likely for patients with lower A or PEst values and higher δ val-
ues. If therapy provides only 10–100-fold LR reductions, a subset
of patients may delay rebound for several months.
Using these cohort-level predictions, we can set efficacy goals
for the reservoir reduction needed to achieve a particular like-
lihood of a desired patient outcome. Fig. 4 provides the target
LRA efficacies for which 50% of patients are predicted to re-
main rebound-free for a specified interruption time. Reductions
of under 10-fold afford patients only a few weeks to a month off
treatment without rebound. For one-year interruptions, a 1,000–
3,000-fold reduction is needed. To achieve the goal of eradication
(cure) a 4-log reduction is required. This value increases to 4.8
logs to cure 75% of patients, and to 5.8 logs for 95% of patients.
Model applications and comparison to data
Current ability to test the model against clinical data is limited
both by the dynamic range of assays measuring LR size and by
the low efficacy of investigational LRA treatments. Yet we can
compare our predictions to results observed for non-LRA-based
interventions that lead to smaller LR size and prolonged treat-
ment interruptions (Fig. 4). A 2010 study of early ART initiators
who eventually underwent treatment interruption found a single
patient with LR size approximately 1,500-fold lower than a typ-
ical patient (0.0064 infectious units per million resting CD4+ T
cells, versus an average of 1 per million) in whom rebound was
delayed until 50 days off treatment [38]. The well-known ‘Berlin
patient’ [22] has remained off treatment following a stem-cell
transplant since 2008, and a comprehensive analysis of his vi-
ral reservoirs found HIV DNA levels at least 7,500-fold lower
than typical patients in the most sensitive assay [39]. The two re-
cently reported ‘Boston patients’ also interrupted treatment, fol-
lowing transplants that caused at least a 3 to 4 log decrease in
viral reservoirs [23]; they have since both rebounded, at approxi-
mately 3 and 8 months post-interruption. In the case of the ‘Mis-
sissippi baby’, infection was discovered and treated within 30
hours of birth, and ART continued until interruption at around
18 months. Virus remained undetectable for 27 months, when vi-
ral rebound occurred, assuming the accuracy of widely reported
claims [40]. At the time of treatment cessation, the LR size was
likely at least 300-fold lower than that of a typical adult (based
on less than 0.017 infectious units per million resting CD4+ T
cells at age 30 months [41], and scaled on a weight basis rel-
ative to adults). These few available cases demonstrate that our
model is not inconsistent with current knowledge. When survival
curves for larger cohorts become available, Bayesian methods can
be used to update estimates in Table 1 and reduce uncertainty of
future predictions.
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Figure 4: Efficacies required for successful LRA therapy. The target LRA
log-efficacy is the treatment level (in terms of log-reduction in latent reser-
voir size) for which at least 50% of patients still have suppressed viral load
after a given treatment interruption length (blue line). Shaded ranges show
the results for the middle 50% (dark gray) and 90% (light gray) of patients.
“Lifetime” means the LR is cleared. Annotations on the curve represent
data points for case studies describing large reservoir reductions and ob-
serving rebound times after ART interruption. From left to right, they rep-
resent a case of early ART initiation in an adult (the “Chun patient” (C.)
[38]), two cases of hematopoietic stem cell transplant with wild-type donor
cells (the two Boston patients (Bo.1 and Bo.2) [23]), a case of early ART
initiation in an infant (the Mississippi baby (Mi.) [41], assuming, as re-
cently reported, rebound after 27 months), and a case of hematopoietic
stem cell transplant with ∆32 CCR5 donor cells (the Berlin patient (Be.)
[22; 39]). For the Chun patient, the annotations represent the maximum
likelihood estimate for LR reduction (diamond), as well as 95% confidence
intervals (vertical bar). For the Boston and Berlin patients, vertical arrows
indicate that only a lower bound on treatment efficacy is known (LR size
was below the detection limit) and that the true value may extend further in
the direction shown. For the Berlin patient, the horizontal arrow indicates
that rebound time is at least five years (rebound has not yet occurred).
Discussion
Our model is the first to quantify the required efficacy of
latency-reversing agents for HIV-1 and set goals for therapy. For
a wide range of parameters, we find that therapies must reduce the
LR by at least two orders of magnitude to meaningfully increase
the time to rebound after ART interruption (upward inflection in
Figs. 2b, 3II), and that reductions of approximately four orders
of magnitude are needed for half of patients to clear the infec-
tion (Figs. 3a, 4). Standard deviations in rebound times of many
months are expected, owing to substantial variation in reactiva-
tion times after effective LRA therapy brings the infection to an
activation-limited regime. While the efficacy required for these
beneficial outcomes is likely beyond the reach of current drugs,
our results permit some optimism: we show for the first time that
reactivation of all cells in the reservoir is not necessary for cessa-
tion of ART. This is because some cells in the LR will die before
reactivating or, following activation, will fail to produce a chain
of infection events leading to rebound. On a more cautionary
note, the wide distribution in reactivation times necessitates care-
ful monitoring of patients, as rebound may occur even after long
periods of viral suppression.
Even without any reservoir reduction, variation in infection pa-
rameters and chance activation together predict delays in rebound
of at least two months in a small minority of patients (Fig. 4),
consistent with ART interruption trials such as SPARTAC [42].
More detailed (and possibly more speculative) models including
specific immune responses may be needed to explain multi-year
post-treatment control, such as found in the VISCONTI cohort
[24].
Our analysis characterizing the required efficacy of LRA ther-
apy does not rely on the specific mechanism of action of these
drugs, only the amount by which they reduce the reservoir. We
have assumed that, after ART/LRA therapy ends, cell activation
and death rates return to baseline. We have also assumed that the
reservoir is a homogeneous population with constant activation
and death rates. The presence of reservoir compartments with dif-
ferent levels of LRA penetration does not alter our results, as they
are stated in terms of total reservoir reduction. If, however, these
compartments vary in activation or death rates [43], or if dynam-
ics of activated cells depends on their source compartment, then
our model may need to be modified. Moreover if spatial popu-
lation structure affects viral replication, viral dynamics above the
detection limit (from which we estimated parameters r and A)
may not correspond straightforwardly to the infection/death rates
in early infection, due to local limitations in target cell density
[44]. Spatial restrictions on viral transmission may be particu-
larly important in densely packed lymphoid tissue [45]. In the
absence of clear understanding of multiple compartments consti-
tuting the LR, we have considered the simplest scenario which
may fit future LRA therapy outcomes.
Throughout this paper, we assume that combination ART is
sufficiently effective so that viral replication alone cannot sustain
the infection after all latent virus is cleared. Studies of treat-
ment intensification [46; 47], of viral evolution during ART
[48; 49], and of in vitro antiviral efficacy [50; 51] all support
this assumption. Moreover, HIV persistence is widely believed
to result solely from the long lifespan or proliferative ability of
latently infected cells [3; 52]. If this assumption is violated,
e.g., by the presence of long-lived drug-protected compartments
[45; 53; 54], then any curative strategy predicated solely on la-
tency reversal would be futile.
Our model also highlights the importance of measuring spe-
cific parameters describing latency and infection dynamics. De-
spite the field’s focus on measuring latent reservoir size with in-
creasing accuracy [55], our results suggest that the rate at which
latently infected cells activate — and the fraction of these that
are expected to establish a rebounding infection — are more pre-
dictive of LRA outcomes. Among all parameters that determine
outcome, the establishment probability is least understood, as it
cannot be measured from viral load dynamics above the limit of
detection. Simply because an integrated provirus is replication-
competent and transcriptionally active does not mean that it will
initiate a growing infection: as with all population dynamics,
chance events dominate early stages of infection growth [56; 57].
HIV-1 transcription is itself a stochastic process, governed by
fluctuating concentrations of early gene products [58]. Sensi-
tive assays of viral outgrowth may pave the way toward under-
standing the importance of these chance events to early infec-
tion; for instance, fluorescent imaging studies of adenovirus have
shown that a large majority of in vitro infections seeded by single
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productively infected cells die out early, before rapid growth and
plaque formation can occur [57]. Similar experiments with HIV
are underway in our laboratory and may help refine parameter
estimates. Keeping other parameters constant, assuming a worst-
case (highest) value for the establishment probability raises the
reservoir reductions required for cure or a desired extended re-
bound time by 0.8 logs. Regardless of the exact probability, the
stochastic nature of HIV-1 activation and infection dynamics im-
plies that even similarly situated patients may experience diver-
gent responses to LRA.
The model can also advise aspects of trial design for LRAs.
Survival curves computed from equation S8 can be used to pre-
dict the probability that a patient is cured, given that they have
been off treatment without rebound for a known period. As fre-
quent viral load testing for years of post-interruption monitoring
is not feasible, it may be helpful to choose sampling timepoints
based on the expected distribution of rebound times. Trial design
is complicated by the fact that LRA treatment efficacy is unknown
if post-treatment LR size is below the detection limit. By consid-
ering prior knowledge about viral dynamics parameters and the
range of possible treatment efficacies, the model may estimate
outcomes even in the presence of uncertainty.
To date, laboratory and clinical studies of investigational LRAs
have generally found weak potential for reservoir reduction —
up to one log-reduction in vitro and less in vivo [12; 26; 59].
We predict that much higher efficacy will be required for eradi-
cation, which may be achieved by multiple rounds of LRA ther-
apy, a combination of therapies, or development of therapies to
which a greater fraction of the LR is susceptible. While we have
focused on LRA therapy, our findings also serve to interpret in-
fection eradication or delays in rebound caused by early treat-
ment [24; 25; 60] or stem cell transplantation [22; 23], both of
which also reduce the latent reservoir. In both of these cases,
however, additional immunological dynamics likely play a ma-
jor role and will need to be incorporated into future models.
We believe that these modeling efforts will provide a quantita-
tive framework for interpreting clinical trials of any reservoir-
reduction strategy.
Methods
Basic stochastic model
The basic model of reservoir dynamics and rebound tracks two
cell types: productively infected activated CD4+ T cells, and la-
tently infected resting CD4+ T cells. The model can be described
formally as a two-type branching process, in which four types of
events can occur (Fig. 1):
Z → Y ... rate constant: a
Z → ∅... rate constant: dz
Y → cY ... rate constant: b× pλ(c)
Y → ∅... rate constant: d
(2)
In this notation Y and Z represent individual actively or latently
infected cells, respectively, ∅ represents no cells, and the arrows
represent one type of cell becoming the other type. A latently
infected cell can either activate (at rate a) or die (at rate dz). An
actively infected cell can either die (at rate d) or produce a col-
lection of virions (at rate b) that results in the infection of c other
cells, where c is a Poisson-distributed random variable with pa-
rameter λ, pλ(c) = (exp(−λ)λc) /(c!). After an infection event,
the original cell dies.
Each event occur independently within a large, constant target
cell population. As the model does not include limitations on vi-
ral growth, it describes only the initial stages of viral rebound.
Since clinical rebound thresholds (plasma HIV RNA > 50 – 200
c ml−1) are well below typical setpoints (104 – 106 c ml−1), this
model suffices to analyze rebound following LRA therapy and
ART interruption. We do not explicitly track free virus, but as-
sume it to be proportional to the number of infected cells. This
assumption is valid because rates governing production of and
clearance of free virus greatly exceed other rates, allowing a sep-
aration of time scales. As we are not interested in blips or other
intraday viral dynamics, this assumption does not influence our
results. A method for calculating the proportionality between free
virus and infected cells is provided in the Supplementary Meth-
ods.
The growth rate of the infection is r = b(λ − 1) − d. The
total death rate of infected cells is dy = b + d, and the basic
reproductive ratio (mean offspring number for a single infected
cell) is R0 = bλ/(b + d). The establishment probability PEst
is the solution to R0
(
1− e−λPEst) − λPEst = 0. The total LR
decay rate in the absence of viral replication is ∆ = a + dz . If
there are Z cells in the latent reservoir, then the number of cells
reactivating per day is A = Za.
Analysis of the model to determine the four key pa-
rameters (δ, A, r, PEst) and rapidly compute survival
curves is provided in the Supplementary Methods. A
script for computation of survival curves is also provided at
http://www.danielrosenbloom.com/reboundtimes.
Parameter estimation
The half-life of latently infected cells has been estimated to be
approximately τ1/2 = 44 months [3; 4]. The resulting value of
δ = ln(2)/τ1/2 is centered at 5.2×10−4 d−1, and we construct a
distribution of values based on ref. [3] . This value represents the
net rate of LR decay during suppressive therapy, considering ac-
tivation, death, homeostatic proliferation, and (presumably rare)
events where activated CD4+ T cells re-enter a memory state.
The net infection growth rate r describes the rate of exponen-
tial increase in viral load once infection has been reseeded. The
LR reactivation rate A is the number of cells exiting the LR per
day, before reservoir-reducing therapy. A and r were jointly es-
timated from the dynamics of viral load during treatment inter-
ruption trials in which there was no additional reservoir-reducing
intervention [5; 34]; in particular, infection growth immediately
following rebound is sensitive to r, while the time to rebound is
sensitive to A. In the absence of reservoir reduction, observed
rebound dynamics are insensitive to PEst, and so this parameter
was instead estimated from population genetic models [35; 36]
that relate observed rates of selective sweeps and emergence of
drug resistance to variance in the viral offspring distribution (see
Supplementary Methods).
6
Simulation of the model
We use the Gillespie algorithm to track the number of latently
and actively infected cells in a continuous time stochastic process.
The initial number of latent cells is Z(0) ∼ Binomial(NLR, q),
where NLR is the pre-treatment reservoir size and q is the effi-
cacy of LRA treatment (fraction of cells remaining). The initial
number of actively infected cells Y(0) is then chosen from a Pois-
son distribution with parameter aZ(0)/dy (corresponding to the
immigration-death equilibrium of the branching process). The
simulation proceeds until the number of actively infected cells
reaches the threshold for clinical detection given by a viral load
of 200 c ml−1 (equivalent to Y = 3× 105 cells total) or until no
active or latent cells remain. Because stochastic effects are impor-
tant only for small Y , we switch to faster deterministic numerical
integration when Y reaches a level where extinction probability
is very low (< 10−4). For each q value we perform 104 to 105
simulations.
Simulations are seeded with values of the key parameters (δ,A,
r, PEst), which may be either the point estimates or random num-
bers sampled from the distributions in Table 1. We then back out
values of the model-specific parameters that are consistent with
the sampled key parameters. In general, we use a pre-therapy
LR size of NLR = 106 cells to get a = A/NLR. We then have
dz = δ − a. As detailed in the Supplementary Methods, sam-
pling PEst requires first sampling the variance-to-mean ratio of
the viral offspring distribution (ρ). Then using r and ρ along with
dy = d + b = 1 day−1, we can get λ, b, d, and PEst. Consis-
tent with our generating function analysis, we find that the spe-
cific values assumed for NLR and dy do not influence the results.
For simulating other models, any other parameter assumptions
are listed in the corresponding supplementary figure captions.
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